Episode 27. Management of PNH
Blood Cancer Talks
00:00
Peg C2Cope Plan for CD55 and CD59
The good news is maybe not for that company, but I think that drug is going to go away in the sense that it's just too cumbersome for patients to use on a regular basis. There's oral complement inhibitors that are coming out that are also upstream that are probably going to take that option away. Even if her hemoglobin is 10.9, she's not having trouble with the always effective life. On the other hand, if she was 8.3 and is spending a lot of time in bed and fatigued and unable to do the things that she was doing before,. That's the type of patient I may offer something like Peg C2Cope plan that can actually address both
Transcript
Play full episode
